Program
CS2009
A development code.
Its studies are led by CStone Pharmaceuticals.
Furthest: phase 2, since Dec 15, 20241 company-led study, 1 open or runningNext primary completion: Jan 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CStone Pharmaceuticals | 11 open or running | phase 2since Dec 15, 2024 | Dec 15, 2024 | Jan 2027phase 2 · NCT06741644 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2024First study: phase 2 study in Advanced Solid TumorsFirst studyNCT06741644 · 800 planned · United States, Australia, China
Ahead
- Jan 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06741644
TargetBeta
“A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06741644Advanced Solid Tumors · United States, Australia, China | 2 | Recruiting | Jan 2027 | 800 |
How it is read
Names in the registry
- “CS2009”, 2 entries
Codes read as this program: CS2009.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.